HCI集团 HCI 深 沪
等待开盘 04-01 09:30:00 美东时间
154.61
-0.600
-0.39%
华盛通- 最 高157.77
- 今 开156.50
- 成交量 12.41万股
- 最 低 154.07
- 昨 收 155.21
- 总市值 20.09亿
- 52周最高 209.70
- 市盈率 静 6.80
- 换手率 0.95%
- 52周最低 135.17
- 委 比 4.17%
- 总股本 1299.20万
- 历史最高 209.70
- 量 比 1.17
- 振 幅 2.38%
- 历史最低 -11.95
- 每 手 1
- 风险率 18.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HCI Group Authorizes Share Buyback Of Up To $80M
The board of directors of HCI Group, Inc. (NYSE:HCI) has authorized a program to repurchase up to $80 million of the company's common shares, subject to market conditions.The program permits the company to
03-03 20:09
HCI Group Authorizes $80 Million Stock Repurchase Program
H. HCI Group, Inc. has authorized an $80 million stock repurchase program, allowing purchases in open markets, block transactions, or private negotiations under applicable securities laws. The program, lasting one year, is discretionary and may be canceled or paused at any time. HCI Group operates in insurance, reinsurance, real estate, claims services, and insurance technology, with shares trading on the NYSE under "HCI." Forward-looking stateme...
03-03 12:00
财报速睇 | HCI集团 2025财年年度营收9.01亿美元，同比增长20.1%；归母净利润2.99亿美元，同比增长171.9%
华盛资讯2月27日讯，HCI集团公布2025财年年度业绩，公司年度营收9.01亿美元，同比增长20.1%，归母净利润2.99亿美元，同比增长171.9%。
02-27 13:56
财报速睇 | HCI集团 2025财年Q4营收2.46亿美元，同比增长52.1%；归母净利润0.98亿美元，同比增长3679.2%
华盛资讯2月26日讯，HCI集团公布2025财年Q4业绩，公司Q4营收2.46亿美元，同比增长52.1%，归母净利润0.98亿美元，同比增长3679.2%。
02-26 06:18
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
Enova, eToro, NP, SLM among week's biggest financials movers
Financial stocks (XLF) largely drifted higher, while the broader S&P 500 slipped in the past week, which was marked by the Federal Reserve's third consecutive interest-rate cut. Enova International (E...
2025-12-13 23:10
Oppenheimer Downgrades HCI Group to Perform
Oppenheimer analyst Michael Phillips downgrades HCI Group (NYSE:HCI) from Outperform to Perform.
2025-11-14 02:06
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
